Results 41 to 50 of about 31,957 (244)

Phosphorylation of protein Tau by GSK3β prolongs survival of bigenic Tau.P301L × GSK3β mice by delaying brainstem tauopathy

Neurobiology of Disease, 2014
Tau.P301L transgenic mice suffer precocious mortality between ages 8 and 11 months, resulting from upper airway defects caused by tauopathy in autonomic brainstem circuits that control breathing (Dutschmann et al., 2010). In individual mice, the clinical
Natalia Crespo-Biel, Clara Theunis, Peter Borghgraef, Benoit Lechat, Herman Devijver, Hervé Maurin, Fred Van Leuven   +6 more
doaj   +1 more source

Targeted brain-specific tauopathy compromises peripheral skeletal muscle integrity and function

Aging Brain
Tauopathies are neurodegenerative disorders in which the pathological intracellular aggregation of the protein tau causes cognitive deficits. Additionally, clinical studies report muscle weakness in populations with tauopathy.
Bryan Alava, Gabriela Hery, Silvana Sidhom, Miguel Gutierrez-Monreal, Stefan Prokop, Karyn A. Esser, Jose Abisambra   +6 more
doaj   +1 more source

Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. [PDF]

, 2016
A152T-variant human tau (hTau-A152T) increases risk for tauopathies, including Alzheimer's disease. Comparing mice with regulatable expression of hTau-A152T or wild-type hTau (hTau-WT), we find age-dependent neuronal loss, cognitive impairments, and ...
Craft, Ryan, Davis, Allyson, Djukic, Biljana, Gill, T Michael, Guo, Weikun, Kim, Daniel, Lo, Iris, Maeda, Sumihiro, Masliah, Eliezer, Mucke, Lennart, Ponnusamy, Ravikumar, Taneja, Praveen, Wang, Xin, Yu, Gui-Qiu   +13 more
core   +2 more sources

Therapeutic VEGFC treatment provides protection against traumatic-brain-injury-driven tauopathy pathogenesis

Cell Reports
Summary: Traumatic brain injury (TBI) increases one’s risk of developing Alzheimer’s disease and tauopathy. Yet, the mechanisms linking TBI to neurodegenerative disease remain poorly defined.
Ana Royo Marco, Katherine R. Bruch, Maureen N. Cowan, Julia G. Dill, Katelyn A. Moore, Ashley C. Bolte, John R. Lukens   +6 more
doaj   +1 more source

Brainstem and Cerebellar Volume Loss and Associated Clinical Features in Progressive Supranuclear Palsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Progressive Supranuclear Palsy (PSP) is a neurodegenerative ‘tauopathy’ with predominating pathology in the basal ganglia and midbrain. Caudal tau spread frequently implicates the cerebellum; however, the pattern of atrophy remains equivocal.
Chloe Spiegel, Timothy P. Siejka, Cassandra Marotta, Josh J. Y. Lee, Kelly Bertram, Terence J. O'Brien, Meng Law, Lucy Vivash, Ian H. Harding   +8 more
wiley   +1 more source

Astrogliopathy in Tauopathies [PDF]

Neuroglia, 2018
Astrocytes are involved in many diseases of the central nervous system, not only as reactive cells to neuronal damage but also as primary actors in the pathological process. Astrogliopathy is a term used to designate the involvement of astrocytes as key elements in the pathogenesis and pathology of diseases and injuries of the central nervous system ...
openaire   +2 more sources

Tau and Tauopathies [PDF]

, 2012
Tauopathies are age-related neurodegenerative diseases that are characterized by the presence of aggregates of abnormally phosphorylated tau. As tau was originally discovered as a microtubule-associated protein, it has been hypothesized that neurodegeneration results from a loss of the ability of tau to associate with microtubules.
Gloria, Lee, Chad J, Leugers
openaire   +2 more sources

Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.
Roxane Dilcher, Charles B. Malpas, Stuart J. McDonald, William T. O’Brien, Craig Despott, Kelly L. Bertram, Matthew P. Pase, Lukas Frontzkowski, Meng Law, Terence J. O’Brien, Lucy Vivash   +10 more
wiley   +1 more source

Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects [PDF]

, 2009
Many neurodegenerative diseases exhibit axonal pathology, transport defects, and aberrant phosphorylation and aggregation of the microtubule binding protein tau. While mutant tau protein in frontotemporal dementia and parkinsonism linked to chromosome 17
Falzone, Tomas Luis, Goldstein, Lawrence S. B., Lillo, Concepción, Rodrigues, Elizabeth M., Stokin, Gorazd B., Westerman, Eileen L., Williams, David S.   +6 more
core   +1 more source

Clinical Validation of Plasma p‐217tau in Neurological Diseases

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari, Hiroo Kasahara, Yoshio Ikeda, Masamitsu Takatama, Mikio Shoji   +13 more
wiley   +1 more source